These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Zidovudine and lamivudine: results of phase III studies. Staszewski S J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Katlama C; Ingrand D; Loveday C; Clumeck N; Mallolas J; Staszewski S; Johnson M; Hill AM; Pearce G; McDade H JAMA; 1996 Jul; 276(2):118-25. PubMed ID: 8656503 [TBL] [Abstract][Full Text] [Related]
6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Stretcher BN Clin Pharmacokinet; 1995 Jul; 29(1):46-65. PubMed ID: 7586898 [TBL] [Abstract][Full Text] [Related]
8. Antiviral therapy of HIV infection. Richman DD Annu Rev Med; 1991; 42():69-90. PubMed ID: 2035995 [TBL] [Abstract][Full Text] [Related]
9. HIV therapy advances. Early antiretroviral therapy. Cooper DA AIDS; 1994 Sep; 8 Suppl 3():S9-14. PubMed ID: 7840916 [TBL] [Abstract][Full Text] [Related]
10. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144 [TBL] [Abstract][Full Text] [Related]
11. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218 [TBL] [Abstract][Full Text] [Related]
12. Duration of the survival benefit of zidovudine therapy in HIV infection. Moore RD; Keruly JC; Chaisson RE Arch Intern Med; 1996 May; 156(10):1073-7. PubMed ID: 8638994 [TBL] [Abstract][Full Text] [Related]
13. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1. Scadden DT; Pickus O; Hammer SM; Stretcher B; Bresnahan J; Gere J; McGrath J; Agosti JM AIDS Res Hum Retroviruses; 1996 Aug; 12(12):1151-9. PubMed ID: 8844019 [TBL] [Abstract][Full Text] [Related]
14. 3TC/AZT: just another combination. GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362997 [TBL] [Abstract][Full Text] [Related]
15. [Response of fetal macrophages in the placenta of pregnant HIV-positive patients with and without antiretroviral treatment]. Villegas Castrejón H; Mayón González J; Paredes Vivas Y; Karchmer S Ginecol Obstet Mex; 1999 May; 67():196-206. PubMed ID: 10363422 [TBL] [Abstract][Full Text] [Related]
16. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. ; de Vincenzi I Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718 [TBL] [Abstract][Full Text] [Related]
17. L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine. Moretti S; Famularo G; Marcellini S; Boschini A; Santini G; Trinchieri V; Lucci L; Alesse E; De Simone C Antioxid Redox Signal; 2002 Jun; 4(3):391-403. PubMed ID: 12215207 [TBL] [Abstract][Full Text] [Related]
18. Rationale for the use of immunotoxins in the treatment of HIV-infected humans. Van Oijen MG; Preijers FW J Drug Target; 1998; 5(2):75-91. PubMed ID: 9588864 [TBL] [Abstract][Full Text] [Related]
19. AZT studies reinforce benefits of combination. AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167 [TBL] [Abstract][Full Text] [Related]
20. Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Crowe S; Cooper DA; Chambers DE Med J Aust; 1996 Mar; 164(5):290-5. PubMed ID: 8628165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]